Clinical trial readout dates for Ultragenyx Pharmaceutical Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2027.
| Phase 3 setrusumab Osteogenesis Imperfecta · NCT06636071 | January 2027 Ongoing |
| Phase 3 No Investigational Product Mucopolysaccharidosis IIIA; MPS IIIA · NCT04360265 | August 2027 Enrolling |
| Phase 3 Triheptanoin Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) · NCT05933200 | August 2027 Ongoing |
| Phase 3 DTX301 OTC Deficiency · NCT05345171 | September 2027 Ongoing |
| Phase 1/2 UX016 GNE Myopathy · NCT07511556 | December 2028 Recruiting |
| Phase 2/3 UX111 MPS IIIA; Sanfilippo Syndrome · NCT02716246 | March 2029 Recruiting |
| Phase 1/2 UX701 Wilson Disease · NCT04884815 | March 2029 Ongoing |
Ultragenyx Pharmaceutical Inc. reported $467M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). Its net loss for that quarter was $118M; at that rate the cash would last about 4 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-03 |